Viridian Therapeutics

Recent news

• Rating change
  Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43
  Market Newswire · 2026/8/5
• Rating change
  Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26
  Market Newswire · 2026/8/10
• Rating change
  Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40
  Market Newswire · 2026/7/1
• Rating change
  Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $39
  Market Newswire · 2026/8/13
• Rating change
  A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $43
  Market Newswire · 2026/6/30
• Rating change
  Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE)
  TipRanks · 2026/6/29
• Rating change
  A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $35
  Market Newswire · 2026/6/29
• Rating change
  Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Hold Rating, Maintains Target Price $20
  Market Newswire · 2026/6/17
• LifeSci Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $35
  Market Newswire · 2026/10/3
• RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38
  Market Newswire · 2026/9/22
• Rating change
  Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/8/14
• Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40
  Market Newswire · 2026/8/20
• Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating
  Market Newswire · 2026/9/1
• Rating change
  A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $41
  Market Newswire · 2026/8/7
• Jefferies Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $30
  Market Newswire · 2026/6/30
• Rating change
  Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $39
  Market Newswire · 2026/8/7
• Rating change
  Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31
  Market Newswire · 2026/7/20
• Rating change
  Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)
  TipRanks · 2026/6/17
• Rating change
  Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $32
  Market Newswire · 2026/6/28
• Rating change
  Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)
  TipRanks · 2026/6/28

Headlines are aggregated automatically and are not independently verified or edited by our team.